Trials / Recruiting
RecruitingNCT06258304
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- GigaGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GIGA-564 | Administered by intravenous infusion |
| DRUG | GIGA-564 | Administered by intravenous infusion |
Timeline
- Start date
- 2024-05-08
- Primary completion
- 2026-04-01
- Completion
- 2027-11-01
- First posted
- 2024-02-14
- Last updated
- 2025-04-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06258304. Inclusion in this directory is not an endorsement.